Archive · 13 Dec 2025
Corona Remedies IPO Listing on Monday
Corona Remedies is a company that makes medicines.
They recently sold some of their shares to the public in something called an IPO.
A lot of people wanted to buy these shares, so the IPO was very popular.
Now, the shares are going to be listed on the stock market for the first time on Monday, December 15.
Before the listing, people are willing to pay more for these shares in a special market called the grey market.
The company makes medicines for women's health, heart and diabetes problems, pain management, and other areas.
They have two factories, one in Gujarat and one in Himachal Pradesh.
The company made a lot of money last year and in the first part of this year.
People who buy shares now might make a profit if the shares sell for more than the price they paid.
However, some experts are worried because nearly half of the IPOs this year are trading below their issue price, which means some people might lose money.
It's important for investors to be careful and choose wisely when buying IPO shares.
Corona Remedies' shares are set to list on the stock exchanges on Monday, December 15, with a significant grey market premium of ₹291 per share.
The IPO was highly subscribed, with a total subscription rate of 144.4 times, and raised ₹655.38 crore from investors.
The estimated listing price is ₹1,353 per share, which is 27.40% higher than the upper band issue price of ₹1,062.
The company operates in the pharmaceutical sector, with offerings in women's health, cardio-diabetes, pain management, and other therapeutic categories.
Corona Remedies reported a net profit of ₹46.19 crore for Q1 FY26 and ₹149.43 crore for FY25, with revenue reaching ₹346.54 crore in Q2 FY26 and ₹1,196.41 crore in FY25.
- Who
- Corona Remedies, a pharmaceutical manufacturer based in Gujarat
- What
- The company's shares are set to list on the stock exchanges on Monday, December 15, with a significant grey market premium
- When
- The IPO subscription period was from December 8 to December 10, and the listing is on December 15
- Where
- The company operates in Gujarat and Himachal Pradesh, with its headquarters in Gujarat
- Why
- The IPO was highly subscribed, with a total subscription rate of 144.4 times, indicating strong investor interest
Optimistic View
Cautious View
IPO Performance
Optimistic View
Corona Remedies' IPO was highly subscribed, indicating strong investor interest and potential for significant gains.
Cautious View
Nearly half of the IPOs this year are trading below their issue price, raising concerns about high valuations and potential losses.
Market Valuations
Optimistic View
The high subscription rate and grey market premium suggest that investors are confident in Corona Remedies' future performance.
Cautious View
Market experts warn about aggressive pricing and the importance of selective investment due to the risk of listing day losses.
- Listing Date
- Monday, December 15
- Grey Market Premium (GMP)
- ₹291 per share
- Estimated Listing Price
- ₹1,353 per share
- Issue Price Range
- ₹1,008–₹1,062 per equity share
- Total Funds Raised
- ₹655.38 crore
- Subscription Rate
- 144.4 times
- QIB Subscription
- 293.80 times
- NII Subscription
- 220 times
- Retail Subscription
- 30.39 times
- Employee Subscription
- 15.56 times
- Share Allocation
- 35% retail, 50% QIB, 15% NII
- Company Headquarters
- Gujarat
- Manufacturing Facilities
- Gujarat and Himachal Pradesh
- Q1 FY26 Net Profit
- ₹46.19 crore
- FY25 Net Profit
- ₹149.43 crore
- Q2 FY26 Revenue
- ₹346.54 crore
- FY25 Total Revenue
- ₹1,196.41 crore
- Total IPOs in 2025
- 97
- IPOs Trading Below Issue Price
- 47
- Total Funds Raised in 2025
- ₹1.83 lakh crore
- Total Funds Raised in 2024
- ₹1.80 lakh crore
- IPO Pipeline for 2026
- ₹1.82 lakh crore